Pharma Pioneer

Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial

29 May 2024
2 min read

Anixa Biosciences, a biotech firm listed on NASDAQ, has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer. This follows the successful treatment of the initial group of patients. The trial, in collaboration with Moffitt Cancer Center, includes patients with recurrent or resistant ovarian cancer who have undergone at least two prior treatments. The innovative therapy, known as CER-T, targets the Follicle Stimulating Hormone Receptor (FSHR), which is present on ovarian cells and tumor vasculature, offering a more specific approach than standard CAR-T treatments.
The first patient in the second cohort received a dosage three times higher than the initial group, with no safety concerns reported thus far. Dr. Amit Kumar, Anixa's CEO, expressed optimism about the potential of their cell therapy in treating solid tumors, a challenge for traditional CAR-T therapies that have shown success in blood-related cancers. Dr. Robert Wenham, the trial's lead investigator, highlighted the specificity of the target and the direct intraperitoneal administration of T-cells, which could reduce side effects like cytokine release syndrome (CRS).
Anixa's therapeutic offerings also include a vaccine in development with the Cleveland Clinic to prevent triple negative breast cancer (TNBC) and ovarian cancer, focusing on immunizing against proteins unique to certain cancers. The company's strategy involves partnering with leading research institutions to explore and commercialize new technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Nuvalent Starts Phase 2 of ALKOVE-1 Trial for ALK-Positive NSCLC and Solid Tumors
Pharma Pioneer
2 min read
Nuvalent Starts Phase 2 of ALKOVE-1 Trial for ALK-Positive NSCLC and Solid Tumors
29 May 2024
Nuvalent has commenced the Phase 2 stage of the ALKOVE-1 clinical trial for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI).
Read →
Protagenic Therapeutics Hits Safety Milestone in Phase I Trial for Stress-Related Disorders Treatment
Pharma Pioneer
2 min read
Protagenic Therapeutics Hits Safety Milestone in Phase I Trial for Stress-Related Disorders Treatment
29 May 2024
Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.
Read →
EyeBio Presents Favorable Restoret Trial Results at Macula Society Meeting
Pharma Pioneer
3 min read
EyeBio Presents Favorable Restoret Trial Results at Macula Society Meeting
29 May 2024
The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
Read →
First Patient Treated in ABILITY-1 Trial of MDNA11 Plus KEYTRUDA® for Advanced Solid Tumors
Pharma Pioneer
3 min read
First Patient Treated in ABILITY-1 Trial of MDNA11 Plus KEYTRUDA® for Advanced Solid Tumors
29 May 2024
Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.